Eikon Therapeutics to Participate in Multiple Investor Conferences in November
Key Highlights
- ➤Eikon executives scheduled to participate in three November investor and biotech conference events
- ➤Roy Baynes to discuss new data and the evolving synthetic lethality landscape November 3
- ➤Roger M. Perlmutter to participate in JP Morgan Biotech Call series November 6
- ➤Roger M. Perlmutter to join Guggenheim Healthcare Innovation Conference fireside chat November 10
Expert Statements
Roger M. Perlmutter, CEO and Board Chair of Eikon Therapeutics
“Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics, will participate in the JP Morgan Chase Biotech Call series and a Guggenheim Investor Conference as listed below:”
Roy Baynes, Chief Medical Officer of Eikon Therapeutics
“Chief Medical Officer, Roy Baynes, M.D., Ph.D., will participate in the Morgan Stanley Biotech Webcast in November:”
* CEO Roger M. Perlmutter, M.D., Ph.D., to participate in Guggenheim 3(rd) Annual Healthcare Innovation Conference Fireside Chat and JP Morgan Biotech Call series * CMO Roy Baynes, M.D., Ph.D., to participate in Morgan Stanley Biotech Webcast discussing new data and the evolving synthetic lethality landscape MILLBRAE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair of Eikon Therapeutics, will participate in the JP Morgan Chase Biotech Call series and a Guggenheim Investor Conference as listed below:
Event: JP Morgan Biotech Call Series Location: Boston, MA Date & Time: November 6, 2026 at 2:00 pm EST Format: Presentation
Get started
Create a free account to read the full story.